Key Highlights

● LeonaBio traded at about $4.84 on October 22, an intraday figure.

● The micro-cap biotech has a market value of roughly $50 million.

● Avalo plunged after AbbVie's skin-disease trial data, according to analysts.

● The S&P 500 health care sector hit a record high.

Shares of LeonaBio (NASDAQ:LONA) slid on Thursday, October 22, 2026, trading at about $4.84 during the session and ranking among the notable decliners on the Nasdaq Composite.

The drop came without company news. LeonaBio did not release trial data, financial results or other announcements tied to the move.

With a market value of roughly $50 million, LeonaBio is a micro-cap biotech. Stocks of this size can be highly volatile on thin news, and steep declines can occur without any identifiable catalyst.

Micro-cap biotech had a bumpy day

LeonaBio had company among small health care stocks moving lower. Avalo Therapeutics (NASDAQ:AVTX) plunged after rival AbbVie (NYSE:ABBV)'s skin-disease trial data raised questions about the class of drug Avalo is developing, according to Cantor and other analysts. Pomdoctor (NASDAQ:POM) reversed a sharp Wednesday gain, and Picard Medical (NYSE American:PMI) also slid with no news.

At the same time, other small biotechs rallied. Biohaven (NYSE:BHVN) jumped after the FDA accepted its resubmitted application for troriluzole in spinocerebellar ataxia, according to a company filing. MoonLake Immunotherapeutics (NASDAQ:MLTX) rose on the same AbbVie readthrough that hurt Avalo, and Korro Bio (NASDAQ:KRRO) climbed on preclinical data.

That split shows how small biotech stocks often trade on company-specific developments, or on none at all, rather than as a single group.

Large health care stocks shone

The broader health care sector had a very different day. The S&P 500 health care sector hit a record high, according to market data, as investors rotated out of technology and into defensive areas. Johnson & Johnson (NYSE:JNJ) was among the leaders of the defensive health care trade among Dow stocks, and Amgen (NASDAQ:AMGN) rose.

That came despite a steep drop in Moderna (NASDAQ:MRNA), one of the weakest performers in the S&P 500. Its shares tumbled after Phase 3 data on a melanoma vaccine it is developing with Merck (NYSE:MRK) appeared before its scheduled presentation. Analysts described the data positively, but some called the reaction a "sell the news" event. A UBS analyst called it "solid data." Full results are due Saturday at the ESMO conference in Madrid.

The Nasdaq's tough session

The Nasdaq Composite closed at 26,008.86, down 694.00 points, its steepest drop since June 5. The decline ended a seven-session winning streak and erased about $1 trillion in market value, according to market data.

AI and chip stocks drove the selloff after the heavy spending plans from Meta Platforms (NASDAQ:META) and Lam Research (NASDAQ:LRCX)'s supply-constrained outlook. The Philadelphia Semiconductor Index posted its biggest one-day drop since June 23.

On the Nasdaq, decliners outnumbered advancers 2,766 to 2,022, with 342 new lows against 82 new highs, according to market data.

The Russell 2000 edged up 3.01 points to 2,784.03, suggesting the weakness in micro-cap biotech was not part of a broad small-cap retreat.

Why tiny biotechs swing

Small drug developers typically have no product revenue and depend on investor funding to pay for trials. Their shares often move on expectations about clinical progress, financing needs and sentiment toward the sector. With limited trading volume, a modest wave of selling can push prices sharply lower.

The $4.84 figure was an intraday snapshot rather than a confirmed close.

LeonaBio Waits on Pipeline and Finance Updates

Investors will look for any update from LeonaBio on its pipeline or finances. For the sector, Saturday's full Moderna and Merck data at ESMO could shape sentiment toward cancer-focused biotechs. Market-wide, the Federal Reserve announces its decision on Wednesday, October 28, and Q3 GDP and September PCE inflation data arrive on October 29.